Metrics to compare | BBOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBOTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | 13.0x | −0.3x | |
PEG Ratio | −0.04 | −0.37 | 0.00 | |
Price / Book | 2.3x | 5.1x | 2.6x | |
Price / LTM Sales | - | 4.3x | 3.1x | |
Upside (Analyst Target) | 158.8% | 17.7% | 47.6% | |
Fair Value Upside | Unlock | 25.8% | 5.6% | Unlock |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.